Literature DB >> 19559572

Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study.

M Jäger1, M Schmauss, G Laux, H Pfeiffer, D Naber, L G Schmidt, W Gaebel, J Klosterkötter, I Heuser, W Maier, M R Lemke, D Degner, G Buchkremer, M Gastpar, H-J Möller, M Riedel.   

Abstract

OBJECTIVE: To examine the predictive validity of early improvement in a naturalistic sample of inpatients and to identify the criterion that best defines early improvement.
METHODS: Two hundred and forty-seven inpatients who fulfilled ICD-10 criteria for schizophrenia were assessed with the Positive And Negative Syndrome Scale (PANSS) at admission and at biweekly intervals until discharge from hospital. Remission was defined according to the recently proposed consensus criteria, response as a reduction of at least 40% in the PANNS total score from admission to discharge.
RESULTS: Receiver operating characteristic (ROC) analyses showed that early improvement (reduction of the PANSS total score within the first 2 weeks of treatment) predicts remission (AUC=0.659) and response (AUC=0.737) at discharge. A 20% reduction in the PANSS total score within the first 2 weeks was the most accurate cut-off for the prediction of remission (total accuracy: 65%; sensitivity: 53%; specificity: 76%), and a 30% reduction the most accurate cut-off for the prediction of response (total accuracy: 76%; sensitivity: 47%; specificity: 90%).
CONCLUSION: The findings of clinical drug trials that early improvement is a predictor of subsequent treatment response were replicated in a naturalistic sample. Further studies should examine whether patients without early improvement benefit from an early change of antipsychotic medication.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19559572     DOI: 10.1016/j.eurpsy.2009.02.005

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  9 in total

Review 1.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

2.  Predictors of Response to Behavioral Treatments Among Children With ADHD-Inattentive Type.

Authors:  Elizabeth B Owens; Stephen P Hinshaw; Keith McBurnett; Linda Pfiffner
Journal:  J Clin Child Adolesc Psychol       Date:  2016-11-02

3.  Predicting functional remission in patients with schizophrenia: a cross-sectional study of symptomatic remission, psychosocial remission, functioning, and clinical outcome.

Authors:  Marcelo Valencia; Ana Fresán; Yoram Barak; Francisco Juárez; Raul Escamilla; Ricardo Saracco
Journal:  Neuropsychiatr Dis Treat       Date:  2015-09-10       Impact factor: 2.570

4.  Empirically driven definitions of "good," "moderate," and "poor" levels of functioning in the treatment of schizophrenia.

Authors:  Haya Ascher-Svanum; Diego Novick; Josep Maria Haro; Jaume Aguado; Zhanglin Cui
Journal:  Qual Life Res       Date:  2012-12-14       Impact factor: 4.147

5.  Toward meeting the needs of homeless people with schizophrenia: the validity of quality of life measurement.

Authors:  Pascal Auquier; Aurelie Tinland; Cecile Fortanier; Anderson Loundou; Karine Baumstarck; Christophe Lancon; Laurent Boyer
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

Review 6.  Clinical predictors of therapeutic response to antipsychotics in schizophrenia.

Authors:  Maren Carbon; Christoph U Correll
Journal:  Dialogues Clin Neurosci       Date:  2014-12       Impact factor: 5.986

7.  A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients.

Authors:  Arantzazu Zabala; Mariana Bustillo; Imanol Querejeta; Marta Alonso; Oiane Mentxaka; Ana González-Pinto; Amaia Ugarte; J Javier Meana; Miguel Gutiérrez; Rafael Segarra
Journal:  J Clin Psychopharmacol       Date:  2017-10       Impact factor: 3.153

8.  Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics.

Authors:  Yi-Lung Chen; Kun-Po Chen; Chih-Chiang Chiu; Ming-Hong Tai; For-Wey Lung
Journal:  BMC Psychiatry       Date:  2018-12-04       Impact factor: 3.630

9.  Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation.

Authors:  Antony Loebel; Leslie Citrome; Christoph U Correll; Jane Xu; Josephine Cucchiaro; John M Kane
Journal:  BMC Psychiatry       Date:  2015-10-31       Impact factor: 3.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.